Search - tctmd.com

Displaying 81 - 94 of 94

$Successful Symetis ACURATE neo valve implantation in a elderly patient with low ejection fraction low-gradient aortic stenosis$

Presentation JIM 2016

Successful Symetis ACURATE neo valve implantation in a elderly patient with low ejection fraction low-gradient aortic stenosis

Presenter: Paolo Pagnotta

February 12, 2016

Presentation JIM 2016

ACURATE Neo: Top-down deployment translates into stable, precise positioning and successful procedures: Symetis TAVI programme highlights

Presenter: Christian Hengstenberg

February 10, 2016

News Industry News

Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

September 12, 2014

Video

» Live Case

Live Case 21: ACURATE NEO Prime XL TAVR Large Annulus - St. Paul’s Hospital, Vancouver BC

June 23, 2023

Video

» Interview

Three-Year Outcomes of the Randomized SCOPE I Trial Comparing the ACURATE Neo Versus the SAPIEN 3 Transcatheter Heart Valve System in Patients With Symptomatic Severe Aortic Stenosis

September 18, 2022

Partner Content

SYNERGY-BP-DES-Optimizing Antiplatelet Therapy After PCI in Complex and High Bleeding Risk Patients - Boston Scientific

November 15, 2019

Partner Content

New Advances in Physiology & Imaging to Optimize Outcomes - Boston Scientific

November 7, 2019

Video

Lessons from the SCOPE I Study and the ACURATE neo2 Body of Evidence

November 7, 2019

Video

ACURATE neo2- Features and Benefits for Optimized TAVR

November 7, 2019

Partner Content

ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients - Boston Scientific

November 4, 2019

Video

ACURATE neo2: Features and Benefits for Optimized TAVR

November 4, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Jonas Lanz About SCOPE I: A Randomized Trial of the ACURATE Neo vs. the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis

September 26, 2019

Partner Content

Optimizing PCI with Coronary Physiology and HD IVUS - Boston Scientific

October 19, 2018

Partner Content

Expanding Treatment Options for Patients with Severe Aortic Stenosis: The Lotus and ACURATE neo Valves

March 8, 2018

Advertisement

Successful Symetis ACURATE neo valve implantation in a elderly patient with low ejection fraction low-gradient aortic stenosis

ACURATE Neo: Top-down deployment translates into stable, precise positioning and successful procedures: Symetis TAVI programme highlights

Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

Live Case 21: ACURATE NEO Prime XL TAVR Large Annulus - St. Paul’s Hospital, Vancouver BC

Three-Year Outcomes of the Randomized SCOPE I Trial Comparing the ACURATE Neo Versus the SAPIEN 3 Transcatheter Heart Valve System in Patients With Symptomatic Severe Aortic Stenosis

SYNERGY-BP-DES-Optimizing Antiplatelet Therapy After PCI in Complex and High Bleeding Risk Patients - Boston Scientific

New Advances in Physiology & Imaging to Optimize Outcomes - Boston Scientific

Lessons from the SCOPE I Study and the ACURATE neo2 Body of Evidence

ACURATE neo2- Features and Benefits for Optimized TAVR

ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients - Boston Scientific

ACURATE neo2: Features and Benefits for Optimized TAVR

Dr. C. Michael Gibson Talks With Dr. Jonas Lanz About SCOPE I: A Randomized Trial of the ACURATE Neo vs. the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis

Optimizing PCI with Coronary Physiology and HD IVUS - Boston Scientific

Expanding Treatment Options for Patients with Severe Aortic Stenosis: The Lotus and ACURATE neo Valves

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content